沐舒坦预防早产儿肺透明膜病

摘要

Purpose　To evaluate the effects of ambroxol on prevention of premature babies with hyaline membrane disease(HMD) with prenatal corticosteroids.　Methods　Premature neonates gestational age 26-36 weeks were divided into two groups,receiving:(1) Ambroxol 30 mg/kg through umbilical vein at birth(group A,n=28) and (2) a control group not given ambroxol (group B,n=35).All the babies were exposed prenatally corticosteroids.　Results　(1) Occurrence rate of HMD in group A was 0%,group B was 11.4%,there was significant difference (P<0.05).(2) Mean fetal age of group A was 32.47+/-4.5 pregnant weeks,group B is 32.86+/-7.1 weeks.No significant difference existed.(3) Different fetal age in gruop B,such as pregnant weeks≤32,33-34,35-36,the HMD rate was separately 28.7%,15.38% and 0%,no case was found in group A.(4) There cases of 12 neonatal asphyxia happened in group B,but none of 6 in group A.　Conclusions　Definite effect can be received by applying ambroxol to prevent premature infant HMD after delivery on the bases of adenotropin before delivery.%目的探讨在应用肾上腺皮质激素的基础上加用沐舒坦预防早产儿肺透明膜病(HMD)的效果。方法设激素+沐舒坦组(n=28)为观察组，单用激素为对照组(n=35)，观察两组早产儿HMD的发生率；观察两组窒息儿中HMD的发生情况及不同胎龄时HMD的发生率。结果 (1) 对照组HMD的发生率为11.4%，观察组为0%，两组有显著性差异(P<0.05)；(2) 对照组中孕周<32周、33～34周及35～36周的早产儿HMD的发生率分别是28.7%、15.38%和0%，而在观察组中均未发生；(3) 对照激素组12例窒息儿中有3人发生HMD，观察组6例窒息儿中无一人发生HMD。结论在产前应用激素的基础上，产后立即加用沐舒坦对预防早产儿HMD有一定的疗效。